Willow Biosciences Inc
TSX:WLLW

Watchlist Manager
Willow Biosciences Inc Logo
Willow Biosciences Inc
TSX:WLLW
Watchlist
Price: 0.17 CAD -5.56%
Market Cap: 107m CAD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

WLLW doesn't have a meaningful market cap.

The Relative Value of one WLLW stock under the Base Case scenario is 0.09 CAD. Compared to the current market price of 0.17 CAD, Willow Biosciences Inc is Overvalued by 50%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

WLLW Relative Value
Base Case
0.09 CAD
Overvaluation 50%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

16.8
P/S
P/S
Price to Sales
16.8
vs History
85
vs Industry
81
Median 3Y
255.1
Median 5Y
346.5
Industry
7.7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-24.7
Median 5Y
-33.1
Industry
24.4
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-28
Median 5Y
-48.8
Industry
21.1
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-25.3
Median 5Y
-39.1
Industry
22.9
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
3
Median 3Y
22.1
Median 5Y
38.9
Industry
3
More Details
16.9
EV/S
EV/S
Enterprise Value to Sales
16.9
vs History
85
vs Industry
70
Median 3Y
250.3
Median 5Y
336.9
Industry
8.2
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.5
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
29
Median 3Y
-24.6
Median 5Y
-43.4
Industry
5.5
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
29
Median 3Y
-21.7
Median 5Y
-35.2
Industry
5.7
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
26
Median 3Y
-27.3
Median 5Y
-48.9
Industry
6.2
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
23
Median 3Y
-25.6
Median 5Y
-48.9
Industry
4.3
More Details
56.5
EV/IC
EV/IC
Enterprise Value to IC
56.5
vs History
92
vs Industry
41
Median 3Y
121.4
Median 5Y
166.1
Industry
5.3
More Details

Multiples Across Competitors

WLLW Competitors Multiples
Willow Biosciences Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Willow Biosciences Inc
TSX:WLLW
107m CAD 16.8 -25.8 -51.4 -34.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 051 945.7 -161 843.8 -196 530.1 -194 287.4
US
Abbvie Inc
NYSE:ABBV
373.2B USD 6.4 100.2 16.4 23.9
US
US BioTec Inc
OTC:USBC
154.1B USD 0 0 0 0
US
Amgen Inc
NASDAQ:AMGN
160.2B USD 4.6 24.2 18.8 18.8
US
Gilead Sciences Inc
NASDAQ:GILD
145.5B USD 5 23.1 10.7 14.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 068.9 -527.9 -574.9 -559.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
101.9B USD 8.9 28 20.6 21.6
AU
CSL Ltd
ASX:CSL
109.4B AUD 4.5 23.5 15.4 19.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
64.1B USD 4.5 14.4 13 14.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
61.1B USD 24.8 -191.3 -479.1 -328.9
P/S Multiple
Revenue Growth P/S to Growth
CA
Willow Biosciences Inc
TSX:WLLW
Average P/S: 3 405 409
16.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
34 051 945.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.4
8%
0.8
US
U
US BioTec Inc
OTC:USBC
Not Available N/A N/A
US
Amgen Inc
NASDAQ:AMGN
4.6
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
5
4%
1.3
US
E
Epizyme Inc
F:EPE
2 068.9
N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
8.9
10%
0.9
AU
CSL Ltd
ASX:CSL
4.5
8%
0.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.5
4%
1.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
24.8
31%
0.8
P/E Multiple
Earnings Growth PEG
CA
Willow Biosciences Inc
TSX:WLLW
Average P/E: 35.6
Negative Multiple: -25.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 843.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
100.2
88%
1.1
US
U
US BioTec Inc
OTC:USBC
Not Available N/A N/A
US
Amgen Inc
NASDAQ:AMGN
24.2
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
23.1
189%
0.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.9 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28
N/A N/A
AU
CSL Ltd
ASX:CSL
23.5
15%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.4
7%
2.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -191.3 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
Willow Biosciences Inc
TSX:WLLW
Average EV/EBITDA: 15.8
Negative Multiple: -51.4 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 530.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.4
14%
1.2
US
U
US BioTec Inc
OTC:USBC
Not Available N/A N/A
US
Amgen Inc
NASDAQ:AMGN
18.8
10%
1.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.7
6%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.9 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.6
17%
1.2
AU
CSL Ltd
ASX:CSL
15.4
12%
1.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13
9%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -479.1 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
Willow Biosciences Inc
TSX:WLLW
Average EV/EBIT: 18.8
Negative Multiple: -34.2 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 287.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.9
28%
0.9
US
U
US BioTec Inc
OTC:USBC
Not Available N/A N/A
US
Amgen Inc
NASDAQ:AMGN
18.8
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
14.8
12%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.5 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.6
17%
1.3
AU
CSL Ltd
ASX:CSL
19.2
16%
1.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.6
10%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -328.9 N/A N/A

See Also

Summary
WLLW intrinsic value, competitors valuation, and company profile.
DCF Valuation
WLLW stock valuation using Discount Cash Flow valuation method.
Relative Valuation
WLLW stock valuation using valuation multiples.
Wall Street Estimates
WLLW price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
WLLW stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 276,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.